Show Summary Details
Page of

(p. 175) Pharmacological Treatments for Schizophrenia 

(p. 175) Pharmacological Treatments for Schizophrenia
(p. 175) Pharmacological Treatments for Schizophrenia

Atheir I. Abbas

and Jeffrey A. Lieberman

Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 October 2020

Schizophrenia, a chronic mental disorder, has a lifetime prevalence rate of approximately 1%. The first antipsychotic drug, chlorpromazine, was introduced in 1954, followed by several similar drugs. With the introduction of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and more recently paliperidone, iloperidone, asenapine, and lurasidone, antipsychotic drugs are often classified as first generation or typical (chlorpromazine-like) versus second generation or atypical (clozapine-like), although the distinction between the two classes, particularly with respect to efficacy, is not as meaningful as initially believed. Both classes have been demonstrated to safely improve psychotic symptoms in the acute phase of the illness and to reduce the risk of relapse in the maintenance phase of treatment. Because of the limited efficacy of antipsychotics in resolving the full range of schizophrenic psychopathology, adjunctive treatments are often used to reduce morbidity. This chapter reviews controlled trials of the pharmacological agents used to treat schizophrenia.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.